Peptides in Women’s Health: A 7-Part Series Starts This Week
Oxytocin and the injectable sold online are both peptides. Over the next few weeks, a 7-part series walks the whole spectrum, from the delivery room to the menopause clinic to the gray market.
Peptides in Women’s Health · Series Introduction
A 7-part series on the peptides that already shape fertility, pregnancy, and menopause, and the booming peptide market that runs years ahead of the evidence.
One word covers the oxytocin in the delivery room and the vial of healing peptide sold online.
The FDA defines a peptide as any chain of 40 amino acids or fewer.1
That single word now stretches across the most trusted drugs in obstetrics and a booming wellness market with almost no evidence behind it. Over the next few weeks, ObGyn Intelligence is running a 7-part series that walks the entire distance between those two ends.
Peptides are not a side topic in women’s health.
They are its backbone, from the brain signal that starts puberty, to the hormone that drives labor, to the new drugs that quiet hot flashes. The problem is that the peptide market has run years ahead of the evidence, and the gap is widest where the stakes are highest: in women who are pregnant, trying to conceive, or moving through menopause. The series sorts the tested from the untested, one stage of life at a time.
What is coming
Part 1. From Oxytocin to Ozempic. The three kinds of peptides in women’s health, established drugs, the body’s own signals, and the gray-market wellness market, and why one word hides all three.
Part 2. The Delivery-Room Peptides We Still Argue About. Oxytocin, carbetocin, and atosiban. After 50 years, we still debate the oxytocin dose, where higher doses raise uterine overstimulation by about a third.2
Part 3. GLP-1 Can Restart Ovulation. That Does Not Make It a Fertility Drug. Why these drugs bring back ovulation in PCOS, what the evidence actually supports, and the surprise pregnancy risk nobody warns about.
Part 4. When to Stop Ozempic Before You Try to Conceive. The three numbers that matter: the 2-month washout,3 the pill interaction, and the 53 percent higher gestational diabetes rate from stopping the drug abruptly.4
Part 5. Real Menopause Peptides vs the Peptide Clinic. The new nonhormonal drugs cut hot flashes by about 73 percent versus 47 percent on placebo,5 and one carries a boxed warning.6 The peptide clinic offers neither the evidence nor a label.
Part 6. The Side Door: BPC-157, Research Peptides, and Compounded GLP-1. The compounding market is closing,7 and litigation has alleged impurities as high as 86 percent.8 What is actually in the vial.
Part 7. The Peptide Playbook. One question to ask at every visit, and a stage-by-stage action plan from trying to conceive through menopause.
How the series works
The series publishes over the coming weeks, one part at a time. In each post, the hook, the topic explainer, and the key stakes are free. The analysis, the specific numbers and doses, the honest limits, and the conclusion are for paid subscribers. The goal is the same every time: give you the numbers your doctor sees, not a watered-down version.
Conclusion
Peptides are quietly running women’s health, and the marketing is louder than the evidence. You do not need to resolve the science to protect yourself. You need to know which peptides have been tested. That is what these seven posts are for. Part 1 starts this week.
Subscribe to get every part as it publishes, including the paid analysis. Share this with someone who is pregnant, planning to conceive, or being sold peptide therapy. The evidence should travel.
References
1. U.S. Food and Drug Administration. Clinical Pharmacology Considerations for Peptide Drug Products. Draft guidance for industry. December 2023. Docket FDA-2023-D-3391.
2. Logue TC, Zullo F, van Biema F, et al. High- vs low-dose oxytocin regimens for labor augmentation: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2025;7(2):101604. doi:10.1016/j.ajogmf.2025.101604. PMID 39788427.
3. WEGOVY (semaglutide) injection prescribing information. Plainsboro, NJ: Novo Nordisk. (Discontinue at least 2 months before a planned pregnancy.)
4. Banerjee M, Dutta S, Dasgupta S. Pre-pregnancy GLP-1 receptor agonist or tirzepatide use and gestational diabetes risk. Diabetes Obes Metab. 2026. doi:10.1111/dom.70853. PMID 42098901.
5. LYNKUET (elinzanetant) prescribing information. Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2025.
6. U.S. Food and Drug Administration. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. Drug Safety Communication. September 12, 2024; boxed warning added December 16, 2024.
7. U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list. News release. April 30, 2026.
8. FDA proposes to exclude GLP-1s from 503B bulk list. Drug Topics. 2026.
Amos Grünebaum, MD / ObGyn Intelligence | obmd.com